KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Debt (2017 - 2025)

Amneal Pharmaceuticals has reported Total Debt over the past 9 years, most recently at $2.6 billion for Q4 2025.

  • Quarterly results put Total Debt at $2.6 billion for Q4 2025, up 7.51% from a year ago — trailing twelve months through Dec 2025 was $2.6 billion (up 7.51% YoY), and the annual figure for FY2025 was $2.6 billion, up 7.51%.
  • Total Debt for Q4 2025 was $2.6 billion at Amneal Pharmaceuticals, roughly flat from $2.6 billion in the prior quarter.
  • Over the last five years, Total Debt for AMRX hit a ceiling of $2.8 billion in Q2 2021 and a floor of $56.9 million in Q1 2021.
  • Median Total Debt over the past 5 years was $2.5 billion (2024), compared with a mean of $1.9 billion.
  • Peak annual rise in Total Debt hit 3734.19% in 2022, while the deepest fall reached 95.5% in 2022.
  • Amneal Pharmaceuticals' Total Debt stood at $85.9 million in 2021, then surged by 2952.35% to $2.6 billion in 2022, then decreased by 2.17% to $2.6 billion in 2023, then fell by 6.98% to $2.4 billion in 2024, then rose by 7.51% to $2.6 billion in 2025.
  • The last three reported values for Total Debt were $2.6 billion (Q4 2025), $2.6 billion (Q3 2025), and $2.2 billion (Q2 2025) per Business Quant data.